MedTrace Logo

Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and Metastasis

NCT01377363 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 236

Last updated 2023-03-10

No results posted yet for this study

Summary

This is a Prospective Clinical Trial without drugs, to determine the HER2 status in the metastasis of patients with primary breast cancer HER2. 32 Sites have been taking part in this Clinical Trial.

Conditions

Sponsors & Collaborators

  • Roche Farma, S.A

    collaborator INDUSTRY

  • Spanish Breast Cancer Research Group

    lead OTHER

Principal Investigators

  • Study Director · Hospital Clinico Universitario de Valencia

  • Study Director · Consorcio Hospitalario Provincial de Castellon

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-11
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01377363 on ClinicalTrials.gov